4 not yet recruiting, 2 completed, 2 recruiting. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Not yet recruiting 4, Completed 2, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Weight Management: new trials by email Literature Review of Weight Management trials Research Report on Weight Management
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet Dose 1, Dose 2 - Food Effect in Healthy Volunteers, Weight Management | Phase 1 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 72 | 2026-11-03 | 2026-11-13 |
| SA030 Injection in Healthy Participants Experimental: 100mg, Experimental: 200mg, Experimental: 400mg - Weight Management | Phase 1 | Not yet recruiting | Suzhou Siran Biotechnology Co.,Ltd. | 24 | 2026-10-16 | 2026-11-13 |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses HRS-1596, HRS-1596 Placebo - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 122 | 2026-09-01 | 2026-09-25 |
| A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants HRS9531 tablets - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 100 | 2026-07-01 | 2026-06-24 |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity ecnoglutide tablets, placebo with matching dosage - Overweight and/or Obesity, Weight Management | Phase 1 / Phase 2 | Recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 126 | 2025-11-18 | 2026-09-16 |
| A Study of YP05002 in Healthy Participants YP05002, Placebo - Weight Management | Phase 1 | Completed | Yaopharma Co., Ltd. | 79 | 2025-08-19 | 2026-07-30 |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) GS-4571, Placebo, Omeprazole - Weight Management | Phase 1 | Recruiting | Gilead Sciences | 134 | 2024-08-28 | 2026-10-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity ASC30, Placebo - Weight Management | Phase 1 | Completed | Ascletis Pharma (China) Co., Limited | 72 | 2024-08-26 | 2025-05-20 |
Diabetes Mellitus, Type 2 (2) · Obesity (2) · Overweight (1)
Nutritional and Metabolic Diseases (4) · Body Weight (2) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutrition Disorders (2) · Overnutrition (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Overweight (1)
Omeprazole (1)
Fujian Shengdi Pharmaceutical Co., Ltd. (2) · Hangzhou Sciwind Biosciences Co., Ltd. (2) · Ascletis Pharma (China) Co., Limited (1) · Gilead Sciences (1) · Suzhou Siran Biotechnology Co.,Ltd. (1) · Yaopharma Co., Ltd. (1)
China (5) · United States (2) · Australia (1)
Jintong Li, Dr (1) · Yiwen Zhang (1)